Biogen Inc. (BIIB)
Biogen Inc.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
Biogen is right in the middle: the good and the not-so-good roughly cancel out.
- What's working
- The stock has been climbing and sits near the top of its range for the year.
- Worth watching
- Its growth over the past year trails most other healthcare companies.
Analyst price target
~12-month · 32 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally…
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 7,500
- Headquarters
- Cambridge, MA
Similar stocks
What’s behind the score
Valuation
P/E 41.3 — lower than 21% of Healthcare peers
P/B 1.8 — lower than 89% of Healthcare peers
P/S 3.4 — lower than 57% of Healthcare peers
EV/EBITDA 12.3 — lower than 63% of Healthcare peers
EV/Revenue 4.1 — lower than 57% of Healthcare peers
PEG 2.4 — lower than 15% of Healthcare peers
FCF yield 3.7% — higher than 41% of Healthcare peers
Profitability & quality
Gross margin 78.3% — higher than 93% of Healthcare peers
Operating margin 25.1% — higher than 57% of Healthcare peers
Net margin 8.3% — higher than 37% of Healthcare peers
ROE 4.6% — higher than 11% of Healthcare peers
ROA 5.2% — higher than 38% of Healthcare peers
Free cash flow is 152% of reported net income
Financial health
Debt/equity 0.4 — lower than 81% of Healthcare peers
Current ratio 1.86 — higher than 76% of Healthcare peers
Quick ratio 0.94 — higher than 52% of Healthcare peers
Cash/debt 0.15 — higher than 28% of Healthcare peers
Debt/EBITDA 2.49 — lower than 48% of Healthcare peers
Growth
Revenue growth 3.4% YoY — higher than 17% of Healthcare peers
Earnings growth -84.8% YoY — higher than 8% of Healthcare peers
Ownership & investor activity
Payout ratio 0.0% — somewhat unusual vs Healthcare peers
Net insider buying, +6.2% of insider shares
Institutions net sold, -11.2% of shares held
Insiders hold 0.2% of shares outstanding
4.5% of float sold short
Momentum
Above its 50- & 200-day averages
92% of the way from its 52-week low to high